- Funding
- USD 30 million upfront retained from Novartis
BioArctic is a Swedish biotech developing treatments for neurodegenerative diseases. Its BrainTransporter technology uses the transferrin receptor to carry antibodies across the blood-brain barrier. On 2 November Novartis ended a deal worth up to USD 802 million, leaving BioArctic with the USD 30 million upfront; its Eli Lilly collaboration continues.